Literature DB >> 25488932

Renal xenobiotic transporter expression is altered in multiple experimental models of nonalcoholic steatohepatitis.

Mark J Canet1, Rhiannon N Hardwick1, April D Lake1, Anika L Dzierlenga1, John D Clarke1, Michael J Goedken1, Nathan J Cherrington2.   

Abstract

Nonalcoholic fatty liver disease is the most common chronic liver disease, which can progress to nonalcoholic steatohepatitis (NASH). Previous investigations demonstrated alterations in the expression and activity of hepatic drug transporters in NASH. Moreover, studies using rodent models of cholestasis suggest that compensatory changes in kidney transporter expression occur to facilitate renal excretion during states of hepatic stress; however, little information is currently known regarding extrahepatic regulation of drug transporters in NASH. The purpose of the current study was to investigate the possibility of renal drug transporter regulation in NASH across multiple experimental rodent models. Both rat and mouse NASH models were used in this investigation and include: the methionine and choline-deficient (MCD) diet, atherogenic diet, fa/fa rat, ob/ob and db/db mice. Histologic and pathologic evaluations confirmed that the MCD and atherogenic rats as well as the ob/ob and db/db mice all developed NASH. In contrast, the fa/fa rats did not develop NASH but did develop extensive renal injury compared with the other models. Renal mRNA and protein analyses of xenobiotic transporters suggest that compensatory changes occur in NASH to favor increased xenobiotic secretion. Specifically, both apical efflux and basolateral uptake transporters are induced, whereas apical uptake transporter expression is repressed. These results suggest that NASH may alter the expression and potentially function of renal drug transporters, thereby impacting drug elimination mechanisms in the kidney.
Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25488932      PMCID: PMC4293398          DOI: 10.1124/dmd.114.060574

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  42 in total

1.  Expression of rat renal cortical OAT1 and OAT3 in response to acute biliary obstruction.

Authors:  Anabel Brandoni; Silvina R Villar; Juan C Picena; Naohiko Anzai; Hitoshi Endou; Adriana M Torres
Journal:  Hepatology       Date:  2006-05       Impact factor: 17.425

2.  Regulation of transporter expression in mouse liver, kidney, and intestine during extrahepatic cholestasis.

Authors:  Angela L Slitt; Katryn Allen; Jennifer Morrone; Lauren M Aleksunes; Chuan Chen; Jonathan M Maher; José E Manautou; Nathan J Cherrington; Curtis D Klaassen
Journal:  Biochim Biophys Acta       Date:  2006-10-26

3.  Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor.

Authors:  Heidi R Kast; Bryan Goodwin; Paul T Tarr; Stacey A Jones; Andrew M Anisfeld; Catherine M Stoltz; Peter Tontonoz; Steve Kliewer; Timothy M Willson; Peter A Edwards
Journal:  J Biol Chem       Date:  2001-11-12       Impact factor: 5.157

4.  Renal elimination of p-aminohippurate (PAH) in response to three days of biliary obstruction in the rat. The role of OAT1 and OAT3.

Authors:  Anabel Brandoni; Naohiko Anzai; Yoshikatsu Kanai; Hitoshi Endou; Adriana Mónica Torres
Journal:  Biochim Biophys Acta       Date:  2006-06-07

5.  Down-regulation of organic anion transporter expression in human hepatocytes exposed to the proinflammatory cytokine interleukin 1beta.

Authors:  Marc Le Vee; Philippe Gripon; Bruno Stieger; Olivier Fardel
Journal:  Drug Metab Dispos       Date:  2007-11-08       Impact factor: 3.922

6.  Ischemia-reperfusion of rat livers decreases liver and increases kidney multidrug resistance associated protein 2 (Mrp2).

Authors:  Yuji Tanaka; Chuan Chen; Jonathan M Maher; Curtis D Klaassen
Journal:  Toxicol Sci       Date:  2007-10-24       Impact factor: 4.849

Review 7.  Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment.

Authors:  Christine Carter-Kent; Nizar N Zein; Ariel E Feldstein
Journal:  Am J Gastroenterol       Date:  2008-01-02       Impact factor: 10.864

8.  Adaptive responses of renal organic anion transporter 3 (OAT3) during cholestasis.

Authors:  Jiarong Chen; Tomohiro Terada; Ken Ogasawara; Toshiya Katsura; Ken-ichi Inui
Journal:  Am J Physiol Renal Physiol       Date:  2008-05-14

9.  Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease.

Authors:  Andrew J Lickteig; Craig D Fisher; Lisa M Augustine; Lauren M Aleksunes; David G Besselsen; Angela L Slitt; Jose E Manautou; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2007-07-19       Impact factor: 3.922

10.  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance.

Authors:  G S Hotamisligil; N S Shargill; B M Spiegelman
Journal:  Science       Date:  1993-01-01       Impact factor: 47.728

View more
  9 in total

1.  Attenuated Ochratoxin A Transporter Expression in a Mouse Model of Nonalcoholic Steatohepatitis Protects against Proximal Convoluted Tubule Toxicity.

Authors:  Joseph L Jilek; Kayla L Frost; Solène Marie; Cassandra M Myers; Michael Goedken; Stephen H Wright; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2021-12-17       Impact factor: 3.579

2.  Effect of nonalcoholic steatohepatitis on renal filtration and secretion of adefovir.

Authors:  Tomas Laho; John D Clarke; Anika L Dzierlenga; Hui Li; David M Klein; Michael Goedken; Stanislav Micuda; Nathan J Cherrington
Journal:  Biochem Pharmacol       Date:  2016-07-02       Impact factor: 5.858

3.  Modulation of Tetrachloroethylene-Associated Kidney Effects by Nonalcoholic Fatty Liver or Steatohepatitis in Male C57BL/6J Mice.

Authors:  Joseph A Cichocki; Yu-Syuan Luo; Shinji Furuya; Abhishek Venkatratnam; Kranti Konganti; Weihsueh A Chiu; David W Threadgill; Igor P Pogribny; Ivan Rusyn
Journal:  Toxicol Sci       Date:  2019-01-01       Impact factor: 4.849

4.  Increased Metformin Clearance in Overweight and Obese Adolescents: A Pharmacokinetic Substudy of a Randomized Controlled Trial.

Authors:  Anne van Rongen; Marloes P van der Aa; Maja Matic; Ron H N van Schaik; Vera H M Deneer; Marja M van der Vorst; Catherijne A J Knibbe
Journal:  Paediatr Drugs       Date:  2018-08       Impact factor: 3.022

5.  Population Pharmacokinetics of Morphine in Patients With Nonalcoholic Steatohepatitis (NASH) and Healthy Adults.

Authors:  V Pierre; C K Johnston; B C Ferslew; Klr Brouwer; D Gonzalez
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-04-18

6.  Altered cisplatin pharmacokinetics during nonalcoholic steatohepatitis contributes to reduced nephrotoxicity.

Authors:  Joseph L Jilek; Kayla L Frost; Kevyn A Jacobus; Wenxi He; Erica L Toth; Michael Goedken; Nathan J Cherrington
Journal:  Acta Pharm Sin B       Date:  2021-06-02       Impact factor: 11.413

Review 7.  Drug Transporters in the Kidney: Perspectives on Species Differences, Disease Status, and Molecular Docking.

Authors:  Wei Zou; Birui Shi; Ting Zeng; Yan Zhang; Baolin Huang; Bo Ouyang; Zheng Cai; Menghua Liu
Journal:  Front Pharmacol       Date:  2021-11-29       Impact factor: 5.810

8.  Physiologically-Based Pharmacokinetic Model of Morphine and Morphine-3-Glucuronide in Nonalcoholic Steatohepatitis.

Authors:  Noora Sjöstedt; Sibylle Neuhoff; Kim L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2020-11-06       Impact factor: 6.875

Review 9.  Extrahepatic Drug Transporters in Liver Failure: Focus on Kidney and Gastrointestinal Tract.

Authors:  Marek Droździk; Stefan Oswald; Agnieszka Droździk
Journal:  Int J Mol Sci       Date:  2020-08-10       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.